Xencor (XNCR) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
27 Apr, 2026Executive summary
Annual Meeting scheduled for June 16, 2026, at 1:00 p.m. Pacific Time at company headquarters in Pasadena, CA.
Proxy materials are available online, with options to request paper or email copies at no charge.
Stockholders can vote via Internet, mail, telephone, or in person at the meeting.
Voting matters and shareholder proposals
Election of nine directors to serve until the next annual meeting and until successors are elected.
Ratification of KPMG LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Approval of amendment to the 2023 Equity Incentive Plan to increase authorized shares by 4,000,000.
Advisory (non-binding) vote on executive compensation as disclosed in the proxy statement.
Board of directors and corporate governance
Board recommends voting "FOR" all director nominees and all proposals.
Nine nominees listed for election, including Dr. Bassil I. Dahiyat and Dr. Raymond J. Deshaies.
Latest events from Xencor
- Key clinical updates on bispecific and TL1A programs signal major advances in immunology and oncology.XNCR
Cantor Global Healthcare Conference 20259 Jul 2026 - XmAb819 achieved 25% response and 70% disease control in advanced ccRCC with good tolerability.XNCR
Study Result8 Jul 2026 - Lead clinical programs show strong efficacy and safety, with pivotal studies planned for 2027.XNCR
Corporate presentation13 May 2026 - Accelerating clinical data and innovation in bispecifics drive pipeline and commercial focus.XNCR
Bank of America Global Healthcare Conference 202612 May 2026 - XmAb942 and XmAb412 advance as next-gen IBD therapies, with pivotal data expected in 2027.XNCR
Digestive Disease Week Conference11 May 2026 - Q1 2026 saw revenue drop, net loss widen, and strong liquidity as clinical milestones approach.XNCR
Q1 20266 May 2026 - Proxy seeks approval for director elections, auditor, equity plan amendment, and executive pay.XNCR
Proxy filing27 Apr 2026 - Advancing bispecific antibody programs in oncology and autoimmune diseases, with pivotal trials ahead.XNCR
Leerink Global Healthcare Conference 202626 Mar 2026 - Lead oncology and immunology assets advance toward pivotal trials and broad commercialization.XNCR
Barclays 28th Annual Global Healthcare Conference11 Mar 2026